BFM
SLS icon

Boothbay Fund Management’s SELLAS Life Sciences SLS Stock Holding History

Boothbay Fund Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,800
Closed -$52K – 2446
2025
Q4 		$52K Buy
+13,800
New +$26.8K ﹤0.01% 1818

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Boothbay Fund Management's SLS Position: Q1 2026 in Review

Boothbay Fund Management sold out of SELLAS Life Sciences (SLS) in Q1 2026, closing a stake of 13,800 shares — an estimated $52K sold.

Boothbay Fund Management first reported a position in SLS in Q4 2025 and held it in 1 quarter. The position peaked at $52K in Q4 2025. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Boothbay Fund Management reported no remaining SELLAS Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 13,800 SELLAS Life Sciences shares in Q1 2026, an estimated $52K.
  • Boothbay Fund Management first reported a position in SELLAS Life Sciences in Q4 2025 and held it in 1 quarter.
  • Boothbay Fund Management's SELLAS Life Sciences position peaked at $52K in Q4 2025.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.